Naloxonazine dihydrochloride is a specific μ-opioid receptor antagonist with an IC₅₀ of 5.4 nM. Naloxonazine dihydrochloride also shows anti-leishmanial activity.

Naloxonazine is relatively stable in solution.
Naloxonazine (72 h) is active against the intracellular amastigote stage of Leishmania donovani with a half maximal inhibitory concentration (GI₅₀) of 3.45 μM.
Naloxonazine (10 μM; 0-72 h) is active at early stages of Leishmania donovani infection.
Naloxonazine affects acidic compartments of the host cell which in turn limit L. donovani intracellular growth.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Naloxonazine (20 mg/kg; i.p.; once) attenuates the increment of locomotor activity induced by acute methamphetamine in mice

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Naloxonazine (20 mg/kg; i.p.; once) attenuates the increment of locomotor activity induced by acute methamphetamine in mice

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Chien CC, et al. Naloxonazine, a specific mu-opioid receptor antagonist, attenuates the increment of locomotor activity induced by acute methamphetamine in mice. Toxicol Lett. 2012 Jul 7;212(1):61-5.  [Content Brief]

  . Hahn EF, et al. Naloxonazine, a potent, long-lasting inhibitor of opiate binding sites. Life Sci. 1982 Sep 20-27;31(12-13):1385-8.  [Content Brief]

  . De Muylder G, et al. Naloxonazine, an Amastigote-Specific Compound, Affects Leishmania Parasites through Modulation of Host-Encoded Functions. PLoS Negl Trop Dis. 2016 Dec 30;10(12):e0005234.  [Content Brief]